Health Economics›Acute myeloid leukemia›First-line induction therapy older or "unfit" patients

First-line induction therapy older or "unfit" patients

Acute myeloid leukemia · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
LoDAC and Venetoclax Variant #01	—	R 283 570	28d	—	8.4 mo	—	—	1
Azacitidine and Venetoclax Variant #01	—	R 199 828	28d	—	14.1 mo	—	—	3
Decitabine and Venetoclax Variant #01	—	R 192 740	28d	—	—	—	—	—
Gemtuzumab ozogamicin monotherapy Variant #04	—	R 122 454	8d	—	4.9 mo	—	—	1
Azacitidine and Gemtuzumab ozogamicin Variant #01	—	R 59 517	8d	—	—	—	—	—
FLAG Variant #01	—	R 21 352	—	—	~6.7 mo	—	—	1
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	9.8 mo	—	—	7
Cytarabine and Etoposide (CYVE) Variant #06	NPM1	R 11 761	—	—	9.2 mo	—	—	—
Decitabine monotherapy Variant #01	—	R 10 907	42d	—	7.7 mo	—	—	2
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Glasdegib and LoDAC Variant #01 Partial	—	R 172	28d	—	8.3 mo	—	—	1
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 172	28d	—	5.1 mo	—	—	7
Clofarabine and LoDAC Variant #01 Partial	—	R 121	49d	—	—	—	—	—
Best supportive care Partial	—	—	—	—	5.8 mo	—	—	5
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	1
CPX-351 monotherapy Variant #01 Partial	—	—	49d	—	9.3 mo	—	—	1

16 of 16 regimens shown